PL2077830T3 - Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej - Google Patents

Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej

Info

Publication number
PL2077830T3
PL2077830T3 PL07843370T PL07843370T PL2077830T3 PL 2077830 T3 PL2077830 T3 PL 2077830T3 PL 07843370 T PL07843370 T PL 07843370T PL 07843370 T PL07843370 T PL 07843370T PL 2077830 T3 PL2077830 T3 PL 2077830T3
Authority
PL
Poland
Prior art keywords
formulations
compositions
treatment
methods
eye disease
Prior art date
Application number
PL07843370T
Other languages
English (en)
Inventor
John Daniel Dobak
Original Assignee
Lithera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lithera Inc filed Critical Lithera Inc
Publication of PL2077830T3 publication Critical patent/PL2077830T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07843370T 2006-10-17 2007-09-27 Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej PL2077830T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85222106P 2006-10-17 2006-10-17
US89800907P 2007-01-29 2007-01-29
US91901107P 2007-03-20 2007-03-20
PCT/US2007/079740 WO2008048770A1 (en) 2006-10-17 2007-09-27 Methods, compositions, and formulations for the treatment of thyroid eye disease
EP07843370A EP2077830B1 (en) 2006-10-17 2007-09-27 Methods, compositions, and formulations for the treatment of thyroid eye disease

Publications (1)

Publication Number Publication Date
PL2077830T3 true PL2077830T3 (pl) 2013-04-30

Family

ID=38701793

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07843370T PL2077830T3 (pl) 2006-10-17 2007-09-27 Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej

Country Status (12)

Country Link
US (3) US20100119609A1 (pl)
EP (2) EP2077830B1 (pl)
JP (5) JP2010506941A (pl)
KR (1) KR101068603B1 (pl)
AU (2) AU2007313077B2 (pl)
CA (2) CA2666612C (pl)
ES (1) ES2398480T3 (pl)
GB (2) GB2443287B (pl)
IL (2) IL198183A (pl)
MX (2) MX2009004198A (pl)
PL (1) PL2077830T3 (pl)
WO (2) WO2008048770A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
EP2429481A4 (en) * 2008-06-25 2014-08-13 Elc Man Llc METHOD AND COMPOSITIONS FOR IMPROVING THE APPEARANCE OF SKIN AND BODY
US8945086B2 (en) * 2008-07-01 2015-02-03 Bruce Becker Retrobulbar needle and methods of use
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
WO2011055944A2 (en) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
MX2012008171A (es) * 2010-01-15 2012-12-17 Lithera Inc Formulaciones aglomeradas liofilizadas.
US9320723B2 (en) 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
GB2485886A (en) * 2010-11-24 2012-05-30 Lithera Inc Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
EP2646012A4 (en) * 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN107880091B (zh) 2012-05-08 2020-12-18 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
US20140308354A1 (en) * 2013-04-12 2014-10-16 Allergan, Inc. Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物
US10906969B2 (en) 2016-06-13 2021-02-02 Massachusetts Eye And Ear Infirmary Local orbital therapy for thyroid eye disease
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
WO2019173352A1 (en) * 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
KR20220018484A (ko) * 2019-06-10 2022-02-15 제니비젼 인크. 시력 장애를 치료하기 위한 방법 및 제형
US10857213B1 (en) * 2019-08-13 2020-12-08 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat a cosmetic condition
CA3152740A1 (en) 2019-08-28 2021-03-04 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
BR112022010038A2 (pt) * 2019-11-26 2022-08-16 Standard Of Care Corp Composições de hialuronidase e métodos de uso das mesmas para tratar o encovamento periorbital e deformidades do sulco lacrimal
US20230302099A1 (en) * 2020-08-20 2023-09-28 Iliana E. Sweis Hyaluronidase fusion proteins comprising a targeting sequence and methods of using same to treat a cosmetic condition
WO2025073804A1 (en) * 2023-10-04 2025-04-10 Rheinische Friedrich-Wilhelms Universität Bonn, Körperschaft Des Öffentlichen Rechts Composition comprising beta-2-adrenergic receptor agonist for transdermal administration

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898330A (en) * 1973-08-01 1975-08-05 Squibb & Sons Inc Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
NZ212204A (en) * 1984-06-04 1988-07-28 Merck & Co Inc Growth-promoting compositions containing hydroxylic compounds
JPH0696521B2 (ja) * 1986-01-31 1994-11-30 千寿製薬株式会社 眼局所投与用眼圧降下剤
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
US5314916A (en) * 1993-04-19 1994-05-24 Alcon Laboratories, Inc. B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) * 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
ES2317657T3 (es) 1996-09-19 2009-04-16 The Regents Of The University Of Michigan Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados.
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
AU737608B2 (en) * 1997-04-30 2001-08-23 Courage Corporation Pty Ltd Composition and methods using an eutomer
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
AU7127600A (en) * 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US6936426B2 (en) * 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
WO2002045688A2 (en) * 2000-12-07 2002-06-13 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2002060410A2 (en) * 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2002088167A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US6726714B2 (en) * 2001-08-09 2004-04-27 Scimed Life Systems, Inc. Stent delivery system
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US6625078B2 (en) * 2002-02-11 2003-09-23 United Memories, Inc. Look-ahead refresh for an integrated circuit memory
ES2318145T3 (es) * 2002-02-19 2009-05-01 Resolution Chemicals Limited Esterilizacion de esteroides por medio de disolventes.
US20050009798A1 (en) * 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US6643212B1 (en) * 2002-04-18 2003-11-04 United Memories, Inc. Simultaneous function dynamic random access memory device technique
US20040028545A1 (en) * 2002-08-06 2004-02-12 Ta-Chin Wang Cylinder assembly for a mini air compressor
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004091540A2 (en) * 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US20040235922A1 (en) * 2003-05-15 2004-11-25 Baile Clifton A. Compositions and methods for inducing adipose tissue cell death
SE0302029D0 (sv) * 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20050069291A1 (en) * 2003-09-25 2005-03-31 Voss James S. Systems and methods for locating a video file
US20050069591A1 (en) * 2003-09-30 2005-03-31 Howard Bernstein Injectable, oral, or topical sustained release pharmaceutical formulations
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
JP5105578B2 (ja) * 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
WO2005046700A1 (ja) * 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
JP2007515402A (ja) 2003-11-20 2007-06-14 アルターアゴン プロプライエタリー リミテッド 哺乳動物および鳥類の体脂肪および体重の減少方法
KR100573828B1 (ko) * 2003-12-29 2006-04-26 주식회사 하이닉스반도체 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20050212152A1 (en) * 2004-03-23 2005-09-29 Reens Daniel J System and method for humidifying homes and commercial sites
US7479481B2 (en) 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2006088134A1 (ja) * 2005-02-18 2006-08-24 Santen Pharmaceutical Co., Ltd. ステロイド化合物の副作用軽減または回避方法
WO2006108176A2 (en) * 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
ES2384641T3 (es) * 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
FR2893845B1 (fr) * 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
US9050368B2 (en) * 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
AU2008331928B2 (en) * 2007-12-03 2012-08-16 Bridge Pharma, Inc. Use of RR/SR-ractopamine
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
MX2012008171A (es) * 2010-01-15 2012-12-17 Lithera Inc Formulaciones aglomeradas liofilizadas.
EP2646012A4 (en) * 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT

Also Published As

Publication number Publication date
MX2009004199A (es) 2009-09-16
IL198183A (en) 2013-09-30
GB0804401D0 (en) 2008-04-16
WO2008067060A3 (en) 2008-08-14
IL198184A0 (en) 2009-12-24
JP2010006837A (ja) 2010-01-14
US20100119609A1 (en) 2010-05-13
IL198183A0 (en) 2009-12-24
EP2076269A2 (en) 2009-07-08
KR20090086409A (ko) 2009-08-12
WO2008048770A1 (en) 2008-04-24
GB2443287A (en) 2008-04-30
CA2666612C (en) 2012-11-27
AU2007313077B2 (en) 2011-06-02
US20160287611A1 (en) 2016-10-06
GB2453188A (en) 2009-04-01
AU2007313077A1 (en) 2008-04-24
WO2008067060A2 (en) 2008-06-05
CA2666564A1 (en) 2008-06-05
GB2443287B (en) 2009-05-27
EP2077830A1 (en) 2009-07-15
EP2077830B1 (en) 2012-11-07
JP2015155423A (ja) 2015-08-27
IL198184A (en) 2015-06-30
JP2015163612A (ja) 2015-09-10
GB0718905D0 (en) 2007-11-07
JP2010506941A (ja) 2010-03-04
AU2007325523A1 (en) 2008-06-05
EP2077830A4 (en) 2010-04-14
US20100137267A1 (en) 2010-06-03
GB2453188B (en) 2010-03-31
WO2008067060A8 (en) 2008-12-31
ES2398480T3 (es) 2013-03-19
JP2012144565A (ja) 2012-08-02
EP2076269A4 (en) 2010-05-19
CA2666612A1 (en) 2008-04-24
KR101068603B1 (ko) 2011-09-30
MX2009004198A (es) 2009-10-19

Similar Documents

Publication Publication Date Title
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IL190779A0 (en) Compositions for treatment of eye diseases
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
IL187405A0 (en) Methods and compositions for the treatment of pain
IL196638A0 (en) Methods and compositions for treating disease
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0618309D0 (en) Compositions and methods for the treatment of disease
ZA200710476B (en) Methods and compositions for the treatment of pain
HK1154911A (en) Methods and compositions for the treatment of huntington's disease
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease
ZA200807049B (en) Compositions and methods for treating collagen-mediated diseases
GB0608007D0 (en) Preparation for the treatment of burns
HK1126673A (en) Uses and compositions for treatment of crohn's disease